Patricia Greninger

15.4k total citations · 3 hit papers
33 papers, 5.2k citations indexed

About

Patricia Greninger is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Patricia Greninger has authored 33 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patricia Greninger's work include Protein Degradation and Inhibitors (7 papers), Neuroblastoma Research and Treatments (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Patricia Greninger is often cited by papers focused on Protein Degradation and Inhibitors (7 papers), Neuroblastoma Research and Treatments (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Patricia Greninger collaborates with scholars based in United States, United Kingdom and Germany. Patricia Greninger's co-authors include Cyril H. Benes, Ultan McDermott, Daniel A. Haber, Mathew J. Garnett, Wanjuan Yang, Howard Lightfoot, Michael R. Stratton, James Smith, Jorge Soares and Simon Forbes and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Patricia Greninger

32 papers receiving 5.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

2012 2.6k citations Wanjuan Yang, Jorge Soares et al. Nucleic Acids Research profile →
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

2009 630 citations Anurag Singh, Patricia Greninger et al. Cancer Cell profile →
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patricia Greninger United States	21	3.7k	1.6k	1.4k	1.4k	529	33	5.2k
Christine A. Pratilas United States	30	3.6k 1.0×	2.0k 1.2×	625 0.4×	933 0.7×	592 1.1×	95	5.0k
Nidhi Bindal United Kingdom	8	5.5k 1.5×	2.0k 1.2×	2.9k 2.0×	1.7k 1.2×	687 1.3×	15	8.0k
Dora Dias‐Santagata United States	44	3.2k 0.9×	3.5k 2.1×	1.6k 1.1×	2.2k 1.5×	295 0.6×	112	7.8k
Shanker Kalyana‐Sundaram United States	23	3.8k 1.0×	875 0.5×	1.6k 1.1×	1.3k 0.9×	153 0.3×	30	5.1k
Sally Bamford United Kingdom	12	5.6k 1.5×	2.1k 1.3×	3.1k 2.2×	1.2k 0.9×	302 0.6×	19	8.1k
Christine M. Lovly United States	44	3.3k 0.9×	3.7k 2.3×	1.4k 1.0×	3.1k 2.2×	201 0.4×	143	6.8k
Poulikos I. Poulikakos United States	27	4.7k 1.3×	2.2k 1.3×	719 0.5×	670 0.5×	744 1.4×	46	6.0k
Mingming Jia China	12	3.7k 1.0×	1.5k 0.9×	2.1k 1.5×	896 0.6×	192 0.4×	19	5.6k
Kimberly Stegmaier United States	38	3.6k 1.0×	1.0k 0.6×	757 0.5×	679 0.5×	216 0.4×	135	5.4k
Mathew J. Garnett United Kingdom	38	7.1k 1.9×	3.1k 1.9×	1.9k 1.3×	1.7k 1.2×	1.5k 2.8×	85	9.8k

Countries citing papers authored by Patricia Greninger

Since Specialization

Citations

This map shows the geographic impact of Patricia Greninger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Greninger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Greninger more than expected).

Fields of papers citing papers by Patricia Greninger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Greninger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Greninger. The network helps show where Patricia Greninger may publish in the future.

Co-authorship network of co-authors of Patricia Greninger

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Greninger. A scholar is included among the top collaborators of Patricia Greninger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Greninger. Patricia Greninger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krytska, Kateryna, Timothy L. Lochmann, Renata Sano, et al.. (2021). Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma. Molecular Cancer Therapeutics. 20(8). 1400–1411. 13 indexed citations

Baro, Marta, Azeet Narayan, Wei Cui, et al.. (2018). Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research. 78(17). 5094–5106. 55 indexed citations

Tillotson, Joseph, Alison Yeomans, Carlos Jiménez‐Romero, et al.. (2018). Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity. Clinical Cancer Research. 24(17). 4256–4270. 36 indexed citations

Yoo, Byunghee, Patricia Greninger, Giovanna T. Stein, et al.. (2018). Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS ONE. 13(7). e0201046–e0201046. 13 indexed citations

Lochmann, Timothy L., Konstantinos V. Floros, Mitra Naseri, et al.. (2017). Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clinical Cancer Research. 24(2). 360–369. 93 indexed citations

Ember, S.W., Que T. Lambert, Norbert Berndt, et al.. (2017). Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics. 16(6). 1054–1067. 41 indexed citations

Lapek, John D., Patricia Greninger, Robert Morris, et al.. (2017). Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nature Biotechnology. 35(10). 983–989. 104 indexed citations

Conery, Andrew R., Richard C. Centore, Archana Bommi‐Reddy, et al.. (2016). Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Research. 76(6). 1313–1319. 23 indexed citations

Rechem, Capucine Van, Joshua C. Black, Patricia Greninger, et al.. (2015). A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors. Cancer Discovery. 5(3). 245–254. 22 indexed citations

10.

Wang, Meng, Patricia Greninger, Anurag Singh, et al.. (2014). EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research. 74(10). 2825–2834. 55 indexed citations

11.

Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →

12.

Wang, Meng, Liliana Gheorghiu, Patricia Greninger, et al.. (2013). EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity. Cancer Research. 73(20). 6254–6263. 35 indexed citations

13.

He, Lei, Kristine Torres‐Lockhart, Nicole Forster, et al.. (2013). Abstract LB-212: Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.. Cancer Research. 73(8_Supplement). LB–212. 1 indexed citations

14.

He, Lei, Kristine Torres‐Lockhart, Nicole Forster, et al.. (2012). Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma. Cancer Discovery. 3(3). 324–337. 54 indexed citations

15.

Yang, Wanjuan, Jorge Soares, Patricia Greninger, et al.. (2012). Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 41(D1). D955–D961. 2597 indexed citations breakdown →

16.

Singh, Anurag, Michael F. Sweeney, Min Yu, et al.. (2012). TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers. Cell. 148(4). 639–650. 222 indexed citations

17.

McDermott, Ultan, A. John Iafrate, Shyamala Maheswaran, et al.. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Research. 69(9). 3937–3946. 83 indexed citations

18.

Galimberti, Fabrizio, Xi Liu, Hua Li, et al.. (2009). Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe. Clinical Cancer Research. 16(1). 109–120. 60 indexed citations

19.

Singh, Anurag, Patricia Greninger, Daniel R. Rhodes, et al.. (2009). A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival. Cancer Cell. 15(6). 489–500. 630 indexed citations breakdown →

20.

McDermott, Ultan, A. John Iafrate, Nathanael S. Gray, et al.. (2008). Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors. Cancer Research. 68(9). 3389–3395. 312 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact